Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

COVID-19 5Neoplasms 2Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Severe Acute Respiratory Syndrome 1Papillomavirus Infections 1Mastocytosis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Hypersensitivity 1Hematologic Neoplasms 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 40Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 32Papillomavirus Vaccines 24Human Papillomavirus Recombinant Vaccine nonavalent 12Vaccines 11Blood Specimen Collection 10Data Collection 9Colposcopy 9Human Papillomavirus DNA Tests 8Specimen Handling 7Radiotherapy, Intensity-Modulated 7Cisplatin 7Surveys and Questionnaires 6Educational Status 6Early Intervention, Educational 6Carboplatin 6Vaginal Smears 5Vaccines, Synthetic 5Methods 5Engerix-B 4fludarabine 3epigallocatechin gallate 3artesunic acid 3artemisinin 3Watchful Waiting 3Polymerase Chain Reaction 3Patient Navigation 3Paclitaxel 3Observation 3Mass Screening 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Papillomavirus Infections × 2019-nCoV Vaccine mRNA-1273 × Clear all
NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Merck Sharp & Dohme LLC

Phase 3 Completed
165 enrolled 13 charts

COVID-19, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡